MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2026.2736542

Медицинская библиотека · Expert opinion on biological therapy · 2026

Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort.

Caso Francesco, Celletti Eleonora, Pantano Ilenia, Mariani Francesco Maria, Shariat Panahi Azadeh, Di Penta Myriam, Ricciardi Riccardo Mattia, Lo Gullo Alberto, Mauro Daniele, Saracino Francesca, Ursini Francesco, Costa Luisa, Scarpa Raffaele, Giacomelli Roberto, Ciccia Francesco, Guggino Giuliana, Cipriani Paola, Ruscitti Piero

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials in psoriatic arthritis (PsA); however, real-world data remain limited. We evaluated the effectiveness and treatment persistence of risankizumab in the GIRRCS cohort.

METHODS

This observational study included 55 consecutive patients with moderate-to-active PsA treated with risankizumab between January 2022 and June 2025. The primary evaluation was 6-month change in Disease Activity Index for Psoriatic Arthritis (DAPSA), assessed using an age- and sex-adjusted linear mixed-effects model. Secondary assessment included longitudinal changes in joint counts, Leeds Enthesitis Index, VAS pain, patient global assessment, and CRP. Drug retention rate (DRR) was estimated by Kaplan-Meier analysis.

RESULTS

Patients had mainly long-standing disease (11.4 ± 9.6 years) and prior biologic exposure (72.7%). DAPSA significantly improved at 6 months (β -9.1, 95%CI - 12.62 to -5.61; p < 0.001). Six-month response was similar between bDMARD-naïve and experienced patients, although earlier improvement at 3 months was observed in naïve individuals (p = 0.021). All secondary assessments improved (p < 0.001). Estimated 18-month DRR was 59.8%.

CONCLUSIONS

Risankizumab was associated with clinical benefit and acceptable treatment persistence, even if larger studies are needed.

Для цитирования: Caso Francesco, Celletti Eleonora, Pantano Ilenia, Mariani Francesco Maria, Shariat Panahi Azadeh, Di Penta Myriam, Ricciardi Riccardo Mattia, Lo Gullo Alberto, Mauro Daniele, Saracino Francesca, Ursini Francesco, Costa Luisa, Scarpa Raffaele, Giacomelli Roberto, Ciccia Francesco, Guggino Giuliana, Cipriani Paola, Ruscitti Piero. Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort.. Expert opinion on biological therapy. 2026. DOI: 10.1080/14712598.2026.2736542.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.